The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. (Q53696647)

18 May 2018

title

The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. (English)

1 reference

18 May 2018

metabolic dysfunction–associated steatotic liver disease

main subject

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

Luciana M A Borém

1

1 reference

18 May 2018

João F R Neto

2

1 reference

18 May 2018

Igor V Brandi

3

1 reference

18 May 2018

Deborah F Lelis

4

1 reference

18 May 2018

Sergio H S Santos

5

1 reference

18 May 2018

publication date

10 April 2018

1 reference

18 May 2018

published in

Hypertension Research

1 reference

18 May 2018

https://scigraph.springernature.com/pub.10.1038/s41440-018-0040-6

exact match

0 references

cites work

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

NAFLD: a multisystem disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Treatment of nonalcoholic steatohepatitis in adults: present and future

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Insulin resistance in obesity as the underlying cause for the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Adipobiology of disease: adipokines and adipokine-targeted pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Interactions between the intestinal microbiome and liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Renin-angiotensin system in the pathogenesis of liver fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The therapeutic role of Renin-Angiotensin System blockers in obesity- related renal disorders

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin-(1-7) and the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The renin-angiotensin-aldosterone system, glucose metabolism and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Renin-angiotensin system: upgrade of recent knowledge and perspectives

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

TLR4 enhances TGF-beta signaling and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Cardiovascular actions of angiotensin-(1-7).

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Renin-angiotensin system revisited

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Increased circulating angiotensin-(1–7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Alamandine: a new member of the angiotensin family

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The renin angiotensin system and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The renin-angiotensin system: a link between obesity, inflammation and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7).

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7).

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The role of renin-angiotensin system modulation on treatment and prevention of liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Local adipose tissue renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II-induced insulin resistance and protein tyrosine phosphatases

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4).

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

The renin-angiotensin and the kallikrein-kinin systems

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Circulating Renin Angiotensin System in Childhood Chronic Renal Failure: Marked Increase of Angiotensin-(1–7) in End-Stage Renal Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Visceral Fat Is an Independent Predictor of All-cause Mortality in Men*

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Gene expression of mineralocorticoid and glucocorticoid receptors in the limbic system is related to type-2 like diabetes in leptin-resistant rats

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats

1 reference

https://api.crossref.org/works/10.1038%2FS41440-018-0040-6

7 January 2021

International union of pharmacology. XXIII. The angiotensin II receptors

1 reference

12 December 2020

AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.

1 reference

12 December 2020

Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4).

1 reference

12 December 2020

Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers

1 reference

12 December 2020

Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.

1 reference

12 December 2020

Pathophysiology of nonalcoholic steatohepatitis

1 reference

12 December 2020

Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells.

1 reference

12 December 2020

Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study

1 reference

12 December 2020

Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan

1 reference

12 December 2020

Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.

1 reference

12 December 2020

10.1038/S41440-018-0040-6

Identifiers

DOI

1 reference

18 May 2018

PubMed ID

29636553

1 reference

18 May 2018